Rituximab-induced thrombocytopenia: A cohort study

European Journal of Haematology

Volumn 89, Issue 3, 2012, Pages 256-266

  Giezen, Thijs J ^a,b,e   Mantel Teeuwisse, Aukje K ^a,b   ten Berg, Maarten J ^c   Straus, Sabine M J M ^b,d   Leufkens, Hubert G M ^a,b   van Solinge, Wouter W ^a,c   Egberts, Toine C G ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Pharmacoepidemiology; Pharmacovigilance; Platelet indices; Postmarketing drug surveillance; Rituximab; Thrombocytopenia

Indexed keywords

RITUXIMAB;

ADULT; ARTICLE; CHILD; CLINICAL PRACTICE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HEALTH CARE PERSONNEL; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK; RISK FACTOR; SCHOOL CHILD; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; COHORT STUDIES; HUMANS; RISK FACTORS; THROMBOCYTOPENIA;

EID: 84865119321     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01808.x     Document Type: Article

References (30)

1. Kenney B, Stack G Drug-induced thrombocytopenia. Arch Pathol Lab Med 2009;133:309-14.
2. Van den Bemt PM, Meyboom RH, Egberts AC Drug-induced immune thrombocytopenia. Drug Saf 2004;27:1243-52.
3. Aster RH, Bougie DW Drug-induced immune thrombocytopenia. N Engl J Med 2007;357:580-7.
4. Kimby E Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-73.
5. European Medicines Agency. European Public Assessment Report MabThera. London 1998. http://www.ema.europa.eu [accessed 23 November 2010].
6. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
7. Stricker BH, Psaty BM Detection, verification, and quantification of adverse drug reactions. BMJ 2004;329:44-7.
8. Ram R, Bonstein L, Gafter-Gvili A, Ben-Bassat I, Shpilberg O, Raanani P Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon. Am J Hematol 2009;84:247-50.
9. Adiyodi J, Thachil J, Hawkins S, Hincks I, Woodcock BE, Salim R Thrombocytopenia with rituximab treatment-splenomegaly as the risk factor. Ann Hematol 2010;89:95-6.
10. Wazny LD, Ariano RE Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient. Pharmacotherapy 2000;20:292-307.
11. Numbenjapon T, Mahapo N, Pornvipavee R, Sriswasdi C, Mongkonsritragoon W, Leelasiri A, Prayoonwiwat W A prospective evaluation of normal mean platelet volume in discriminating hyperdestructive thrombocytopenia from hypoproductive thrombocytopenia. Int J Lab Hematol 2008;30:408-14.
12. Kaito K, Otsubo H, Usui N, Yoshida M, Tanno J, Kurihara E, Matsumoto K, Hirata R, Domitsu K, Kobayashi M Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia. Br J Haematol 2005;128:698-702.
13. Ntaios G, Papadopoulos A, Chatzinikolaou A, et al. Increased values of mean platelet volume and platelet size deviation width may provide a safe positive diagnosis of idiopathic thrombocytopenic purpura. Acta Haematol 2008;119:173-7.
14. Wilop S, Galm O, Dada R, Osieka R, Jost E Rituximab-associated changes in platelet count in patients with non-Hodgkin lymphoma. Leuk Lymphoma 2008;49:2116-24.
15. Otrock ZK, Mahfouz RA, Oghlakian GO, Salem ZM, Bazarbachi A Rituximab-induced acute thrombocytopenia: a report of two cases. Haematologica 2005;90(Suppl):ECR23.
16. Ten Berg MJ, Huisman A, Van den Bemt PM, Schobben AF, Egberts AC, Van Solinge WW Linking laboratory and medication data: new opportunities for pharmacoepidemiological research. Clin Chem Lab Med 2007;45:13-9.
17. Muller R, Mellors I, Johannessen B, Aarsand AK, Kiefer P, Hardy J, Kendall R, Scott CS European multi-center evaluation of the Abbott Cell-Dyn sapphire hematology analyzer. Lab Hematol 2006;12:15-31.
18. National Cancer Institute. http://www.cancer.gov [accessed 29 December 2010].
19. Bowles KM, Cooke LJ, Richards EM, Baglin TP Platelet size has diagnostic predictive value in patients with thrombocytopenia. Clin Lab Haematol 2005;27:370-3.
20. Ten Berg MJ, Huisman A, Van den Bemt PM, Den Breeijen H, Egberts TC, Van Solinge WW Discriminative value of platelet size indices for the identification of the mechanism of chemotherapy-induced thrombocytopenia. Biomarkers 2011;16:51-7.
21. De Keulenaer BL, Cheah CY Comment on "Drug-induced thrombocytopenia: an updated systematic review". Drug Saf 2009;32:707; author reply 708.
22. Cheah CY, De Keulenaer B, Leahy MF Fluoroquinolone-induced immune thrombocytopenia: a report and review. Intern Med J 2009;39:619-23.
23. Hoffman MA Clinical presentations and complications of hairy cell leukemia. Hematol Oncol Clinic North Am 2006;20:1065-73.
24. Golomb HM, Catovsky D, Golde DW Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med 1978;89(5 Pt 1):677-83.
25. Thieblemont C, Felman P, Callet-Bauchu E, Traverse-Glehen A, Salles G, Berger F, Coiffier B Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003;4:95-103.
26. Pittaluga S, Verhoef G, Criel A, Wlodarska I, Dierlamm J, Mecucci C, Van den Berghe H, De Wolf-Peeters C "Small" B-cell non-Hodgkin's lymphomas with splenomegaly at presentation are either mantle cell lymphoma or marginal zone cell lymphoma. A study based on histology, cytology, immunohistochemistry, and cytogenetic analysis. Am J Surg Pathol 1996;20:211-23.
27. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian E Long-term follow-up of patients with chronic lymphocytic leukaemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998;92:1165-71.
28. Luo EJ, Levitt L Massive splenomegaly. Hospital Physician 2008;00:31-8.
29. Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Borlenghi E, Ungari M, Ruggeri G, Rossi G Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatment. Leuk Lymphoma 2006;47:1013-7.
30. Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P The late adverse events of rituximab therapy - rare but there! Leuk Lymphoma 2009;50:1083-95.